These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11836041)

  • 1. A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine.
    Smolders RG; Vogelvang TE; Mijatovic V; van Baal WM; Neele SJ; Netelenbos JC; Kenemans P; van der Mooren MJ
    Maturitas; 2002 Feb; 41(2):105-14. PubMed ID: 11836041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women.
    Anderson PW; Cox DA; Sashegyi A; Paul S; Silfen SL; Walsh BW
    Maturitas; 2001 Jul; 39(1):71-7. PubMed ID: 11451623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.
    Gol M; Akan P; Dogan E; Karas C; Saygili U; Posaci C
    Maturitas; 2006 Feb; 53(3):252-9. PubMed ID: 15990257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.
    Mijatovic V; van der Mooren MJ; Kenemans P; de Valk-de Roo GW; Netelenbos C
    Menopause; 1999; 6(2):134-7. PubMed ID: 10374220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of raloxifene on activated protein C (APC) resistance in postmenopausal women and on APC resistance and homocysteine levels in elderly men: two randomized placebo-controlled studies.
    Duschek EJ; Neele SJ; Thomassen MC; Rosing J; Netelenbos C
    Blood Coagul Fibrinolysis; 2004 Oct; 15(8):649-55. PubMed ID: 15613919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raloxifene reduces impedance to flow within the uterine artery in early postmenopausal women: a 2-year randomized, placebo-controlled, comparative study.
    Post MS; van der Mooren MJ; van Baal WM; Neele SJ; Netelenbos JC; Kenemans P
    Am J Obstet Gynecol; 2001 Sep; 185(3):557-62. PubMed ID: 11568777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homocysteine in postmenopausal women and the importance of hormone replacement therapy.
    Mijatovic V; van der Mooren MJ
    Clin Chem Lab Med; 2001 Aug; 39(8):764-7. PubMed ID: 11592448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women.
    Vogelvang TE; Mijatovic V; van der Mooren MJ; Pinsdorf U; von Bergmann K; Netelenbos JC; Lütjohann D
    Maturitas; 2005 Apr; 50(4):312-20. PubMed ID: 15780532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life.
    Voss S; Quail D; Dawson A; Bäckström T; Aguas F; Erenus M; The HS; Bonnar J; De Geyter C; Hunter M; Nickelsen T;
    BJOG; 2002 Aug; 109(8):874-85. PubMed ID: 12197366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study.
    Davis SR; O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Thiebaud D
    Menopause; 2004; 11(2):167-75. PubMed ID: 15021446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
    Palomba S; Orio F; Russo T; Falbo A; Tolino A; Manguso F; Nunziata V; Mastrantonio P; Lombardi G; Zullo F
    Osteoporos Int; 2005 Aug; 16(8):943-52. PubMed ID: 15739035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women.
    Mijatovic V; Netelenbos C; van der Mooren MJ; de Valk-de Roo GW; Jakobs C; Kenemans P
    Fertil Steril; 1998 Dec; 70(6):1085-9. PubMed ID: 9848300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raloxifene and hormone replacement therapy increase arachidonic acid and docosahexaenoic acid levels in postmenopausal women.
    Giltay EJ; Duschek EJ; Katan MB; Zock PL; Neele SJ; Netelenbos JC
    J Endocrinol; 2004 Sep; 182(3):399-408. PubMed ID: 15350182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.
    Nickelsen T; Creatsas G; Rechberger T; Depypere H; Erenus M; Quail D; Arndt T; Bonnar J;
    Climacteric; 2001 Dec; 4(4):320-31. PubMed ID: 11770189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of hormone therapy on plasma homocysteine levels: a randomized clinical trial.
    Tutuncu L; Ergur AR; Mungen E; Gun I; Ertekin A; Yergok YZ
    Menopause; 2005 Mar; 12(2):216-22. PubMed ID: 15772570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene Lowers Plasma Lipoprotein(a) Concentrations: a Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials.
    Ferretti G; Bacchetti T; Simental-Mendía LE; Reiner Ž; Banach M; Sahebkar A
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):197-208. PubMed ID: 28265881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.
    Walsh BW; Kuller LH; Wild RA; Paul S; Farmer M; Lawrence JB; Shah AS; Anderson PW
    JAMA; 1998 May; 279(18):1445-51. PubMed ID: 9600478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women.
    Vogelvang TE; Leurs JR; van der Mooren MJ; Mijatovic V; Hendriks DF; Neele SJ; Netelenbos JC; Kenemans P
    Menopause; 2004; 11(1):110-5. PubMed ID: 14716191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause.
    Shlipak MG; Simon JA; Vittinghoff E; Lin F; Barrett-Connor E; Knopp RH; Levy RI; Hulley SB
    JAMA; 2000 Apr; 283(14):1845-52. PubMed ID: 10770146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative vascular effects of hormone replacement therapy and raloxifene in women at increased cardiovascular risk.
    Cerquetani E; Vitale C; Mercuro G; Fini M; Zoncu S; Rosano GM
    Gynecol Endocrinol; 2004 Jun; 18(6):291-8. PubMed ID: 15497491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.